Kseniya Yu. Kokina

Kseniya Yu. Kokina

Auto-generated profile, based on publicly available information

Kseniya Yu. Kokina

Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
PBPavel Bogomolov
Pavel Bogomolov
AAAlexander Alexandrov
Alexander Alexandrov
NVNatalia Voronkova
Natalia Voronkova
MMMaria Macievich
Maria Macievich
KKKsenia Kokina
Ksenia Kokina
SUStephan Urban
Stephan Urban

13 December 2017 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
EMEkaterina E. Mishina
Ekaterina E. Mishina
AMAlexander Y. Mayorov
Alexander Y. Mayorov
PBPavel O. Bogomolov
Pavel O. Bogomolov
MMMaria V. Matsievich
Maria V. Matsievich
KKKsenia Y. Kokina
Ksenia Y. Kokina
БВБоголюбова Аполлинария Васильевна
Боголюбова Аполлинария Васильевна
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are pathological conditions that are co-occurring, and have been reaching epidemic proportions. One of the most significant risk factors for the development of both T2DM and NAFLD is obesity, which increases existing insulin resistance (IR). IR thought to be one of the main pathogenic causes linking T2DM and NAFLD. In recent years, there has been increased interest in obtaining non-invasive methods for assessing fibrosis and determining indications for liver biopsy, such as the NAFLD fibrosis score, extended liver fibrosis panel, and transient elastography. However, liver biopsy remains the gold standard for diagnosing NAFLD. Given that patients with T2DM are at higher risk of NAFLD than the general population, and that the presence of diabetes is a risk factor for the progression of NAFLD, patients with T2DM should be more closely monitored by clinicians. The present review paper is devoted to the search for causeeffect relationships of concurrent diseases such as NAFLD and disorders of carbohydrate metabolism, and priority areas of diagnosis of NAFLD.

31 January 2019 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
PBPavel O. Bogomolov
Pavel O. Bogomolov
KKKseniya Yu. Kokina
Kseniya Yu. Kokina
AMAleksander Yu. Mayorov
Aleksander Yu. Mayorov
EMEkaterina E. Mishina
Ekaterina E. Mishina
АМА. Ю. Майоров
А. Ю. Майоров
Non-alcoholic fatty liver disease (NAFLD) is the most commonly diagnosed hepatopathy. There is an increase in the incidence of NAFLD in the structure of liver diseases in children and adolescents, which is directly related to the increasing prevalence of obesity. The spectrum of liver tissue changes in NAFLD ranges from benign hepatocellular steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis of the liver, and hepatocellular carcinoma. With the increasing prevalence of NAFLD in children, we can expect an increase in the incidence of adverse outcomes among people of working age. The key problem for NAFLD is the prediction of disease outcomes. In epidemiological and genetic studies, the relationship between the morphological stage of NAFLD and hereditary factors is shown. Currently, there are three genes associated with NAFLD (PNPLA3, TM6SF2, and GCKR), which, together with the genes responsible for insulin resistance, lipid deposition, inflammation and fibrogenesis in hepatocytes, determine the phenotype of fatty liver disease. The article considers the modern understanding of the issues of genetics, development of liver steatosis and progression of NASH. It is expected that this knowledge can transform our risk stratification strategies in patients with NAFLD and help identify new therapeutic goals.

12 December 2019 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KKK. Yu. Kokina
K. Yu. Kokina
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
ASA. B. Sidorenko
A. B. Sidorenko
YMYa. G. Moisyuk
Ya. G. Moisyuk
ЮМЮ. О. Малиновская
Ю. О. Малиновская
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Recent statistics have shown increased rates of morbidity and mortality from Clostridium difficile infection worldwide. This problem is mainly typical for surgical patients and is associated with an antibiotic therapy and a prolonged hospital stay. Recipients of solid organs are at a high risk of developing severe forms of C. difficile infection due to immunosupression. Existing recommendations for the treatment of C. difficile infection are based on the severity of the disease and do not consider patients after liver transplantation. The aim of this work is to determine an actual tactics for the diagnosis and treatment of C. difficile in organ recipients in clinical practice.

14 March 2018 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Open access
PBP. O. Bogomolov
P. O. Bogomolov
MMM. V. Macievich
M. V. Macievich
KKKsenia Y. Kokina
Ksenia Y. Kokina
AMA. Yu. Mayorov
A. Yu. Mayorov
EME. E. Mishina
E. E. Mishina
Non-alcoholic fatty liver disease (NAFLD) affected 20-40% of the adult population in high developed countries. Active form of the disease - non-alcoholic steatohepatitis (NASH) - is characterized by damaged hepatocytes, inflammation of the liver tissue, can be accompanied by liver fibrosis, and is one of the most common causes of liver cirrhosis, liver failure and hepatocellular carcinoma. Moreover, there is a close link between NASH and metabolic syndrome, thereby among this category of patients the high risk of developing diabetes mellitus, cardiovascular complications and cancer. Weight reduction of 10% by observing dietary recommendations and performing regular physical exercises contributes to the reduction or complete resolution of NASH in some patients. However, in practice, it is not always possible to eliminate inflammation in the hepatic tissue. Existing drugs such as vitamin E, pioglitazone and pentoxifylline have limited efficacy, and can cause a few side effects, including hepatotoxicity, and not to reduce the severity of liver fibrosis. However, basic and translational studies have improved our understanding of the pathogenesis of NASH, thereby opening new promising therapeutic targets. Currently, several drug agents are in Phase II and Phase III clinical trials and may enter practice in the foreseeable future. In this article, we consider modern concepts of pathogenesis, existing therapeutic approaches and new directions of pharmacy in the field of NASH treatment.

24 June 2024 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
KKK. Yu. Kokina
K. Yu. Kokina
OSO. V. Sumtsova
O. V. Sumtsova
AGA. O. Grigorevskaya
A. O. Grigorevskaya
YMYa. G. Moysyuk
Ya. G. Moysyuk
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Introduction. Impaired liver transplant function in the long term often leads to graft loss and the recipient death. There are many causes for the development of a late liver allograft dysfunction and different types of its clinical presentation, but there is no generally accepted definition. This hinders its timely diagnosis, analysis of its prevalence, and also makes it difficult to compare the performance of transplantation programs.Objective. To determine the clinical and prognostic value of late liver allograft dysfunction.Material and methods. The study included 103 cases of cadaveric liver transplantation from donors diagnosed with brain death to 100 recipients, of whom 36% were men, aged 48 years old (40;56) (18–68) at the time of transplant, having MELD score 17 (14;21) (7–41). The follow-up period was 52 months (20;77) (8–180). The cases where the graft loss occurred earlier than 3 months were excluded.The late liver allograft dysfunction was defined as a dysfunction of the transplanted liver, which was manifested by at least one of three following signs and occurred at more than 3 months after transplantation: 1) increased aspartate aminotransferase, alanine aminotransferase and/or gamma glutamyl transferase, alkaline phosphatase, bilirubin; 2) impaired synthetic function (increased international normalized ratio, decreased antithrombin III, cholinesterase); 3) liver cirrhosis complications (signs of portal hypertension, ascites, encephalopathy). The following limits were chosen as a diagnostic threshold for laboratory parameter abnormalities: more than 2 upper limits of normal for total bilirubin, more than 1.5 upper limits of normal for the levels of alanine or aspartic aminotransferases, more than 1.5 upper limits of normal for gamma-glutamyltransferase or alkaline phosphatase, more than 1.6 of normal for international normalized ratio.Results. Late liver allograft dysfunction was diagnosed at least once in 64% of recipients. Through the postoperative course, the proportion of patients with late dysfunction varied from 22% to 40%. The etiology of late liver allograft dysfunction was viral (38%), unknown (25%), biliary (19%), immune (17%), and vascular (1%). Late liver allograft dysfunction was reversible in 75% of cases, persistent in 17%, progressive in 8% of cases. Progressive late liver allograft dysfunction led to a graft loss in all cases observed.Recipients with late liver allograft dysfunction were found to have had a 33% higher incidence of early allograft dysfunction (OR 4.7, 95% CI [1.8–12.3]); the incidence of biliary dysfunction was 3.1 times higher with distant choledochojejunostomy (OR 3.9, 95% CI [1.1–13.9]); in patients with autoimmune and cholestatic disease, the incidence of immune dysfunction was 4.8 times higher (OR 5.8, 95% CI [1.7–20.3]).Conclusion. The progressive nature of late liver allograft dysfunction negatively affects the results of transplantation and therefore should be considered as an indication for retransplantation. Reversible and persistent variants of late liver allograft dysfunction have favorable) prognosis. If the etiology of late dysfunction is not established, the regular surveillance with monitoring for fibrosis and repeated attempts to clarify the diagnosis should be continued.